Nintedanib offers a glimmer of hope for patients living with pulmonary fibrosis

This editorial discusses how the drug nintedanib slows the worsening of dyspnea and fatigue, stabilizes the impact of pulmonary fibrosis, and may improve cough. This is important for patients with pulmonary fibrosis to understand the risks and benefits of therapy, including how treatments may affect their quality of life. Anna Podolanczuk, MD, received a Dalsemer Award and Kerri Aronson, MD, received a Catalyst Award.